List All Pancreatic Cancer Trials

Pancreatic Cancer

 

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Closed;   Study ID: NCT01839487

FOLFIRINOX w/wo Hyperacute®-Pancreas Immunotherapy for Pancreatic Cancer (8028)
A Phase III Study Of FOLFIRINOX With Or Without Hyperacute®-Pancreas (algenpantucel-L) Immunotherapy In Subjects With Borderline Resectable Or Locally Advanced Unresectable Pancreatic Cancer

Investigator: Andrew Coveler, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01836432

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone for Patients With Resected Pancreatic Cancer (20140859)
A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01964430

Combination Chemotherapy w w/o PEGPH20 for Pancreatic Cancer (SWOG 1313)
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Pending;   Study ID: NCT01959139

90Y-Clivatuzumab Tetraxetan + Low-Dose Gemcitabine for Metastatic Pancreatic Cancer (20151371)
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

Investigator: Andrew Coveler, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01956812

Neoadjuvant Chemotherapy followed by Stereotactic Body Radiation Therapy with Algenpantucel-L Immunotherapy in Subjects for Pancreatic Cancer (20150183)
An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects with Borderline Resectable Pancreatic Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02405585

Afatinib Dimaleate and Capecitabine for Solid Tumors, Pancreatic Cancer or Biliary Cancer (9078)
Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Investigator: Gabriela Chiorean. MD;   Conditions: Bile Duct Carcinoma, Recurrent Pancreatic Carcinoma, Solid Neoplasm, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02451553